Each delivery route has practical differences beyond clinical efficacy that may influence which option is best for a given patient
Individuals receiving therapeutic B12 injections or taking high-dose oral supplements without medical supervision face the greatest risk of very high levels
The statements made regarding these supplements have not been evaluated by the Food and Drug Administration (FDA)
Secondary haemochromatosis also includes dysmetabolic iron overload syndrome (DIOS), linked to metabolic syndrome, mild ferritin elevation, and normal transferrin saturation
Required evidence may include clinical studies, extensive post-marketing use data, expert advice, and the views of relevant health professionals and public associations
FDA's 2024 review states the mechanism of action is still unknown, which limits how confidently any specific physiological effect can be predicted in humans